Radiopharm Theranostics (ASX:RAD) has achieved a milestone in its ongoing clinical development program for its radiotherapeutic asset, 177Lu-RAD204.
Radiopharm Theranostics accelerates 177Lu-RAD204 Phase 1 dose escalation trial
May 12, 2025 Australian Biotech
Latest Video
New Stories
-
Pharmac minister sworn in as New Zealand's Deputy Prime Minister
June 1, 2025 - - Latest News -
An opportunity for reflection on the need to humanise PBS decision-making
June 1, 2025 - - Latest News -
Ipsen's Julien Dagher promoted to European leadership role
June 1, 2025 - - Latest News -
Daiichi Sankyo secures certification as Great Place to Work
June 1, 2025 - - Latest News -
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News